Methods of treating inflammatory and/or autoimmune disease

• US 7,261,894 B2
• Filed: 11/18/2004
• Issued: 08/28/2007
• Est. Priority Date: 08/21/1998
• Status: Expired due to Fees

• Current Assignee: Immunex Corporation (Amgen Inc.)
• Original Assignee: Immunex Corporation (Amgen Inc.)
• Inventors: Smith, Dirk E, Sims, John E
• Primary Examiner(s): O'Hara; Eileen
• Assistant Examiner(s): HAMUD, FOZIA M
• Application Number:
  US10/991,812
• Publication Number:
  US 20050208051A1
• Time in Patent Office: 1,013 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/545 IL-1
• CPC Class Codes: C07K 16/245 IL-1

Abstract

The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.

Claims

1. A method of treating an individual afflicted with an inflammatory and/or autoimmune disease selected from the group consisting of asthma, inflammatory bowel disease, psoriasis, and combinations thereof, comprising administering to the individual an antagonistic antibody immunoreactive with IL-1 epsilon comprising the amino acid sequence set forth in SEQ ID NO:

8 or 13, wherein the antibody decreases induction of a biological activity of the IL-1 epsilon selected from the group consisting of;

expression of one or more cytokines selected from the group consisting of IL-1 alpha, IL-1 beta, TNF-alpha, IL-10, IFN-gamma, IL-12 p40, IL-6;

expression of one or more cell-surface molecules selected from the group consisting of ICAM-1, TLR4, TLR5, TLR9, DC-B7; and

activation of one or more signaling molecules selected from the group consisting of NFkappaB, p38 MAP kinase, Stress-Activated Protein Kinase (SAPK/JNK).

2. The method of claim 1, wherein inflammatory and/or autoimmune disease is selected from the group consisting of:

Crohn'"'"'s Disease, ulcerative colitis, psoriatic arthritis, psoriasis, asthma, and combinations thereof.

3. The method of claim 2, wherein the antibody is a monoclonal antibody.

4. The method of claim 3, wherein the monoclonal antibody is selected from the group consisting of chimeric antibody, a humanized antibody,a human antibody, and an antigen-binding fragment of the aforementioned antibodies.

5. The method of claim 1, wherein the antibody is a monoclonal antibody.

6. The method of claim 5, wherein the monoclonal antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, a human antibody, and an antigen-binding fragment of the aforementioned antibodies.